Ulcerative colitis natural history, complications and prognosis
Jump to navigation
Jump to search
|
Ulcerative colitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Ulcerative colitis natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Ulcerative colitis natural history, complications and prognosis |
|
FDA on Ulcerative colitis natural history, complications and prognosis |
|
CDC on Ulcerative colitis natural history, complications and prognosis |
|
Ulcerative colitis natural history, complications and prognosis in the news |
|
Blogs on Ulcerative colitis natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahad Hasan, M.D.[2] Usama Talib, BSc, MD [3]
Overview
Ulcerative colitis (UC) is a lifelong relapsing–remitting disease with no reliable medical cure; proctocolectomy is the only definitive cure.[1] In population-based cohorts, the cumulative risk of relapse is approximately 70–80% at 10 years, about 10–15% of patients follow an aggressive course, nearly half require at least one UC-related hospitalization, and the 5- and 10-year cumulative risk of colectomy is approximately 10–15%.[2] Major complications include acute severe ulcerative colitis with toxic megacolon, perforation or massive hemorrhage, venous thromboembolism, extraintestinal manifestations, and colitis-associated colorectal cancer (CRC).[3] Contemporary CRC risk is substantially lower than historical referral-center estimates, and surveillance colonoscopy is risk-stratified, beginning 8 years after symptom onset or at diagnosis of primary sclerosing cholangitis (PSC).[4][5] Large nationwide cohorts show a modest excess all-cause mortality (adjusted HR ~1.4 in Sweden), although relative mortality has declined over time.[6]
Natural History
Disease Extent and Proximal Extension
- Left-sided colitis is the most frequent distribution at diagnosis.[2] Across population-based cohorts, 30–60% present with proctitis, 16–45% with left-sided colitis, and 14–35% with extensive colitis.[1]
- Proximal extension occurs in 10–30% of patients over time, approximately 10–19% at 5 years and 11–28% at 10 years.[2][7]
- Fewer than 5% of patients are later reclassified as Crohn's disease.[1][2]
Clinical Course
- Most patients have a mild-to-moderate course that is most active at diagnosis, followed by variable periods of remission or mild activity.[2]
- Cumulative relapse risk is approximately 70–80% at 10 years; about 10–15% of patients experience an aggressive course.[2]
- UC is increasingly regarded as a progressive disease: persistent inflammation is associated with phenotypic extension, structural bowel damage, colorectal dysfunction, neoplasia, hospitalization, and colectomy.[8]
Predictors of an Aggressive Course
- Younger age at onset (<40 years); onset after age 60 tends to be milder[1]
- Extensive colitis
- Deep ulcerations and failure to achieve mucosal healing
- High perinuclear antineutrophil cytoplasmic antibody (pANCA) titers
- Fever or weight loss at diagnosis, short interval to first flare, and active disease in the preceding year[9]
Hospitalization and Colectomy
- Almost 50% of patients require UC-related hospitalization, and the 5-year risk of re-hospitalization is ~50%.[2]
- Within 5 years of diagnosis, ~20% of patients are hospitalized and ~7% undergo colectomy.[4]
- The 5- and 10-year cumulative colectomy risk is ~10–15%; older estimates of 20–40% reflect pre-biologic, referral-center populations. Achieving mucosal healing is associated with a lower colectomy risk.[2]
Complications
Acute Complications
- Acute severe ulcerative colitis may be complicated by toxic megacolon (nonobstructive colonic dilatation, classically of the transverse colon, with systemic toxicity), bowel perforation, and massive hemorrhage.[3][10]
- Venous thromboembolism risk is increased, particularly during active disease and hospitalization.[3]
Chronic Complications
- Structural damage: benign strictures, pseudopolyps, a shortened ahaustral ("lead-pipe") colon, colonic dysmotility, and anorectal dysfunction.[1][8]
- Hematologic: iron deficiency anemia and anemia of chronic disease.[3]
- Neoplasia: dysplasia and colitis-associated CRC (see below).
Extraintestinal Manifestations
Extraintestinal manifestations (EIMs) are common; one review estimated EIMs, including PSC, in approximately 27% of patients with UC.[4]
- Musculoskeletal: peripheral arthropathy, sacroiliitis, ankylosing spondylitis
- Cutaneous: erythema nodosum, pyoderma gangrenosum
- Ocular: episcleritis, uveitis
- Hepatobiliary: primary sclerosing cholangitis
- Oral: aphthous ulcers[3]
Colorectal Cancer
Magnitude of Risk
- UC confers approximately a 1.7-fold higher CRC risk than the general population, with a cumulative risk of ~4.5% at 20 years.[4]
- Contemporary cumulative estimates (~1%, ~3%, and ~7% at 10, 20, and 30 years) are substantially lower than the classic referral-center estimates (2%, 8%, and 18%).[10]
- In population-based cohorts, ~1.5% of patients were diagnosed with CRC after 15 years of follow-up.[2]
- Isolated proctitis carries little or no excess risk.[11]
Risk Factors for Colitis-Associated Neoplasia
- Longer disease duration and greater anatomic extent
- Cumulative inflammatory burden (severity and persistence of endoscopic/histologic inflammation), an independent and modifiable risk factor[8]
- Concomitant PSC
- Family history of CRC, especially a first-degree relative diagnosed before age 50
- Colonic stricture, dense pseudopolyposis, prior dysplasia, and a tubular/shortened colon[12][5]
Primary Sclerosing Cholangitis
- PSC occurs in a minority of patients with UC, whereas most patients with PSC have inflammatory bowel disease, most commonly UC; the association is bidirectional.[13][4]
- PSC-associated UC is a distinct phenotype: often extensive but endoscopically mild colitis with right-sided predominance, rectal sparing, and backwash ileitis.[1]
- CRC risk is approximately 4-fold higher in UC with PSC than in UC alone.[14]
- Long-term outcome in PSC-UC is driven largely by hepatobiliary disease, including end-stage liver disease, cholangiocarcinoma, and need for liver transplantation.[13]
- Whether colectomy modifies PSC progression or post-transplant recurrence is uncertain; observational data conflict, and colectomy decisions are driven by colonic indications.[13]
Prognosis
Mortality
- A meta-analysis of population-based inception cohorts found no significant excess overall mortality but increased mortality from gastrointestinal causes.[15]
- Larger nationwide cohorts show a modest excess: in Sweden, all-cause mortality in UC was increased (HR ~1.4), relative mortality declined over time, and incident IBD cases diagnosed 2002–2014 had an estimated life span 2.3 years shorter than matched comparators.[6] UK primary-care data also show increased mortality in IBD compared with matched controls.[16]
- Individuals with UC have a lower life expectancy than the general population.[4]
Morbidity and Quality of Life
- Chronic diarrhea, rectal bleeding, fatigue, and work disability substantially impair quality of life even when survival is near-normal.[4][2]
Prognostic Modifiers
- Proctitis and limited left-sided disease carry a comparatively benign course and little excess CRC risk; extensive colitis, young onset, and PSC mark higher-risk phenotypes.[1][11]
- Mucosal healing is associated with lower colectomy risk, and reducing cumulative inflammatory burden lowers neoplasia risk.[2][8]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF (2017). "Ulcerative colitis". Lancet. 389 (10080): 1756–1770. doi:10.1016/S0140-6736(16)32126-2. PMID 27914657.
- ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ (2018). "Natural history of adult ulcerative colitis in population-based cohorts: a systematic review". Clin Gastroenterol Hepatol. 16 (3): 343–356.e3. doi:10.1016/j.cgh.2017.06.016. PMID 28625817.
- ↑ 3.0 3.1 3.2 3.3 3.4 Danese S, Fiocchi C (2011). "Ulcerative colitis". N Engl J Med. 365 (18): 1713–1725. doi:10.1056/NEJMra1102942. PMID 22047562.
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 Gros B, Kaplan GG (2023). "Ulcerative colitis in adults: a review". JAMA. 330 (10): 951–965. doi:10.1001/jama.2023.15389. PMID 37698559 Check
|pmid=value (help). - ↑ 5.0 5.1 Murthy SK, Feuerstein JD, Nguyen GC, Velayos FS (2021). "AGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases: Expert Review". Gastroenterology. 161 (3): 1043–1051.e4. doi:10.1053/j.gastro.2021.05.063. PMID 34416977 Check
|pmid=value (help). - ↑ 6.0 6.1 Olén O, Askling J, Sachs MC, Neovius M, Smedby KE, Ekbom A, Ludvigsson JF (2020). "Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964-2014". Gut. 69 (3): 453–461. doi:10.1136/gutjnl-2018-317572. PMID 31092591.
- ↑ Magro F, Rodrigues A, Vieira AI, Portela F, Cremers I, Cotter J, Correia L, Duarte MA, Tavares ML, Lago P, Ministro P, Peixe P, Lopes S, Garcia EB (2012). "Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts". Inflamm Bowel Dis. 18 (3): 573–583. doi:10.1002/ibd.21815.
- ↑ 8.0 8.1 8.2 8.3 Krugliak Cleveland N, Torres J, Rubin DT (2022). "What does disease progression look like in ulcerative colitis, and how might it be prevented?". Gastroenterology. 162 (5): 1396–1408.
- ↑ Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ (2012). "Ulcerative colitis". Lancet. 380 (9853): 1606–1619. doi:10.1016/S0140-6736(12)60150-0. PMID 22914296.
- ↑ 10.0 10.1 Holubar SD, Lightner AL, Poylin V, Vogel JD, Gaertner W, Davis B, Davis KG, Mahadevan U, Shah SA, Kane SV, Steele SR, Paquette IM, Feingold DL (2021). "The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Surgical Management of Ulcerative Colitis". Dis Colon Rectum. 64 (7): 783–804. doi:10.1097/DCR.0000000000002037. PMID 33853087 Check
|pmid=value (help). - ↑ 11.0 11.1 Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD (2019). "ACG Clinical Guideline: Ulcerative Colitis in Adults". Am J Gastroenterol. 114 (3): 384–413. doi:10.14309/ajg.0000000000000152. PMID 30840605.
- ↑ Shah SC, Itzkowitz SH (2022). "Colorectal cancer in inflammatory bowel disease: mechanisms and management". Gastroenterology. 162 (3): 715–730.e3. doi:10.1053/j.gastro.2021.10.035. PMID 34757143 Check
|pmid=value (help). - ↑ 13.0 13.1 13.2 Shen B, Wang S, Farokhian A (2025). "Clinical association between inflammatory bowel disease and primary sclerosing cholangitis: what changes after colectomy and liver transplantation?". eGastroenterology. 3 (3): e100199. doi:10.1136/egastro-2025-100199. PMID 40791845 Check
|pmid=value (help). - ↑ Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO (2002). "Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis". Gastrointest Endosc. 56 (1): 48–54. doi:10.1067/mge.2002.125367. PMID 12085034.
- ↑ Jess T, Gamborg M, Munkholm P, Sørensen TI (2007). "Overall and cause-specific mortality in ulcerative colitis: meta-analysis of population-based inception cohort studies". Am J Gastroenterol. 102 (3): 609–617. doi:10.1111/j.1572-0241.2006.01000.x. PMID 17156150.
- ↑ King D, Reulen RC, Thomas T, Chandan JS, Thayakaran R, Subramanian A, Gokhale K, Bhala N, Nirantharakumar K, Adderley NJ, Trudgill N (2020). "Changing patterns in the epidemiology and outcomes of inflammatory bowel disease in the United Kingdom: 2000-2018". Aliment Pharmacol Ther. 51 (10): 922–934. doi:10.1111/apt.15701.